Genmab A/S (NASDAQ:GMAB) on Monday said it will discontinue further clinical development of acasunlimab.

The decision was made as part of Genmab’s strategic focus on the most value‑creating opportunities in its late‑stage portfolio and following a thorough assessment of the evolving competitive landscape.

While the clinical profile observed to date has been encouraging, Genmab will concentrate resources on programs with the highest potential impact, including Epkinly (epcoritamab), petosemtamab, and rinatabart sesutecan (Rina‑S), which are advancing in late‑stage development.

Also Read: Major Victory For Genmab As Epkinly Receives FDA Approval For Type Of Pretreated Blood Cancer

The decision does ...